China Medical GatewayLoading your healthcare gateway…

Li Yan Bing

Li Yan Bing — Chief Physician — Endocrinology — Zhongshan First Hospital

Specialties

Specializes in the diagnosis and treatment of endocrine and metabolic diseases such as diabetes, thyroid diseases (hyperthyroidism, hypothyroidism, thyroiditis, thyroid nodules), pituitary-adrenal diseases, secondary hypertension, growth and development disorders, and osteoporosis.

Education

Graduated from Zhongshan Medical University in 1984, underwent master's and doctoral training. From 2002 to 2003, studied at the University of Alabama at Birmingham (UAB) in the United States for one year.

Professional Experience

He has long been engaged in research on short-term intensive insulin therapy to reverse early type 2 diabetes. In 2000, he was the first in China to innovatively apply short-term intensive insulin therapy as the initial treatment for type 2 diabetes. The related results were published in Diabetes Care (2004, 2012, impact factor 14.8), significantly improving patient prognosis and inducing diabetes remission. Subsequently, through nationwide multi-center studies, the important role of short-term intensive insulin therapy (SIIT) in diabetes treatment models was further established, with the research results published in The Lancet (2008, impact factor 98.4). He was the first in China to propose the 'precision step-down treatment model' for type 2 diabetes. Through in-depth analysis, he identified a series of clinical markers that can achieve long-term glycemic remission and summarized insulin dosages and blood glucose characteristics during intensive therapy. Related research results were published in Endocr J (2013), Diabetes Technol Ther (2013), Diabetes Res Clin Prac (2015, 2017), J Diabetes Res (2016), and J Diabetes (2023), among other journals. His team has continuously explored the optimization, improvement, and mechanism research of intensive insulin regimens, refining and standardizing the intensive therapy process. Since 2017, based on previous research results, he has led the team to formulate the 'intensive-simplified' treatment strategy and verified it through nationwide multi-center randomized controlled trials. The studies found that this strategy significantly improves patients' glycemic control, with results clearly superior to current conventional treatment strategies; the findings were published in BMJ (2024, impact factor 93.6). The team has established the largest domestic and international cohort (over 2,000 cases), with the longest follow-up and the most comprehensive data, for newly diagnosed type 2 diabetes subjected to short-term intensive insulin therapy. The research results have been adopted in multiple editions of the Chinese Diabetes Prevention and Treatment Guidelines (2013–2024), becoming an important basis for the insulin short-term intensive treatment pathway and post-intensive therapy glucose-lowering regimen selection for newly diagnosed patients, having a profound impact on the methods and concepts of type 2 diabetes treatment. In addition, he led the writing of the 'Expert Consensus on Short-Term Intensive Insulin Therapy to Reverse Type 2 Diabetes' and the 'Expert Consensus on Short-Term Intensive Insulin Therapy for Type 2 Diabetes (2021 Edition)', which sparked strong reactions in the field. At the same time, he spearheaded the establishment of the Short-Term Intensive Insulin Therapy Specialty Alliance and the Guangdong Diabetes Reversal Management Alliance, effectively promoting the standardization of intensive therapy and diabetes reversal efforts.

Professional Roles

Deputy Director of the Endocrinology Branch of the Chinese Medical Association Chairman of the Endocrinology Branch of the Guangdong Medical Association Deputy Director of the Diabetes and Microcirculation Professional Committee of the Chinese Society for Microcirculation Leader of the China Insulin Secretion Research Group National-level medical leading talent of Guangdong Province, Excellent Talent of Guangdong Province Chief Expert of the National Key Project on Major Chronic Diseases Third Chairman of the Diabetes Branch of the Guangdong Medical Association Chairman of the Metabolism and Endocrinology Professional Committee of the Guangdong Health Management Society Member of the Guangdong Provincial Cadres Health Care Expert Group Director of the Key Laboratory of the Guangdong Provincial Health Department Head of the National Pharmacology Base for Endocrinology at Sun Yat-sen First Hospital

Return to Home